Liquid Biopsy in Ovarian Cancer
- Women's Cancer Research Foundation
- Jul 20, 2022
- 1 min read
Updated: Jan 12, 2024
In recent years there have been considerable efforts to develop a blood test or liquid biopsy (a simple and non-invasive alternative to surgical biopsies which enables doctors to discover a range of information about a tumor through a simple blood sample) that could detect multiple cancers.
Ovarian cancer detection would benefit patients if early-stage disease or early recurrence could be identified by such a blood test. Technology that examines circulating DNA in the blood is being explored. A clinical validation study revealed the overall sensitivity of the detection of all ovarian cancers via a liquid biopsy at 83.1% for stage I ovarian cancer, indicating that this approach may not provide a robust detection of early-stage ovarian cancer. Currently, it is not known if using a liquid biopsy to detect early-stage ovarian cancer will be effective in reducing patient mortality.
More Ovarian Cancer Information:
About Women’s Cancer Research Foundation
The Women’s Cancer Research Foundation (WCRF) is one of the most active research organizations in the nation. We are dedicated to studying and evaluating novel treatments for women afflicted with breast, ovarian, endometrial, and cervical cancers. The WCRF persistently endeavors to make a difference in women’s lives by offering them hope, strength, and progress.
Laguna Beach, CA 92651
PH: (949) 642-5165
Follow Us On Social Media:
Comments